Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology.

Ryvu Therapeuctis was founded in 2007 and currently employs 170 scientists, including 80 Ph.Ds. Ryvu was previously known as Selvita, until renamed to Ryvu Therapeutics after spin out of the services segment.

The company is headquartered in Kraków, Poland. Ryvu Therapeutics is developing therapeutics that address clinical limitations of current treatments in oncology. Their work is defined by deep scientific knowledge, organizational efficiency, and a high throughput discovery engine platform.